These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25311263)

  • 61. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
    Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of combined 18F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: a multicenter analysis.
    Lococo F; Cesario A; Okami J; Cardillo G; Cavuto S; Tokunaga T; Apolone G; Margaritora S; Granone P
    Lung Cancer; 2013 Nov; 82(2):245-51. PubMed ID: 23992878
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer.
    Tanizaki Y; Kobayashi A; Shiro M; Ota N; Takano R; Mabuchi Y; Yagi S; Minami S; Terada M; Ino K
    Int J Gynecol Cancer; 2014 Mar; 24(3):454-60. PubMed ID: 24463640
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fluorodeoxyglucose Positron Emission Tomography Can Provide Useful Information for Differentiating Thymic Epithelial Tumors.
    Tomita M; Ayabe T; Tsuchiya K; Nakamura K
    Thorac Cardiovasc Surg; 2018 Jun; 66(4):345-349. PubMed ID: 28728209
    [TBL] [Abstract][Full Text] [Related]  

  • 65. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
    Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
    Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[
    Tabata K; Nishie A; Shimomura Y; Isoda T; Kitamura Y; Nakata K; Yamada Y; Oda Y; Ishigami K; Baba S
    Clin Radiol; 2022 Jun; 77(6):436-442. PubMed ID: 35410786
    [TBL] [Abstract][Full Text] [Related]  

  • 67.
    Shen K; Yu M; Ji Y; Zhou X; Liu B; Zhang W; Su R; Qi J; Wang Q; Xue W
    Prostate; 2023 Sep; 83(12):1167-1175. PubMed ID: 37189301
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 69. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
    Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
    BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size.
    Murakami S; Saito H; Sakuma Y; Mizutani Y; Ishikawa Y; Kondou T; Oshita F; Yokose T; Kameda Y; Suga Y; Ito H; Tsuboi M; Nakayama H; Noda K; Yamada K
    Eur J Radiol; 2010 Aug; 75(2):e62-6. PubMed ID: 20005653
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors.
    Ohnona J; Nataf V; Gauthe M; Balogova S; Belissant Benesty O; Zhang-Yin J; Talbot JN; Montravers F
    Neoplasma; 2019 Jan; 66(1):140-148. PubMed ID: 30509093
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
    Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM
    AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Utility of early dynamic and delayed post-diuretic
    Sharma A; Mete UK; Sood A; Kakkar N; Gorla AK; Mittal BR
    Br J Radiol; 2017 Apr; 90(1072):20160787. PubMed ID: 28256904
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 18F-FDG PET/CT and nestin expression as prognostic tools in pulmonary neuroendocrine tumours.
    Bromińska B; Czepczyński R; Gabryel P; Jarmołowska-Jurczyszyn D; Janicka-Jedyńska M; Sawicka-Gutaj N; Gut P; Bromiński G; Dyszkiewicz W; Ruchała M
    Nucl Med Commun; 2019 Apr; 40(4):353-360. PubMed ID: 30640182
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea.
    Cho JH; Ryu JK; Song SY; Hwang JH; Lee DK; Woo SM; Joo YE; Jeong S; Lee SO; Park BK; Cheon YK; Han J; Kim TN; Lee JK; Moon SH; Kim H; Park ET; Hwang JC; Kim TH; Jeon TJ; Cho CM; Choi HS; Lee WJ
    Pancreas; 2016 Aug; 45(7):941-6. PubMed ID: 26765964
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors.
    Partelli S; Rinzivillo M; Maurizi A; Panzuto F; Salgarello M; Polenta V; Delle Fave G; Falconi M
    Neuroendocrinology; 2014; 100(4):293-9. PubMed ID: 25301162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.